SLS Stock Snaps 2-Day Slide: Sellas’ SLS009 AML Trial Spotlights Big Pharma Drug Combo From ABBV, RHHBY And BMY
Sellas Life Sciences (SLS) stock rose 2% to $13.76 after updating its SLS009 trial for AML, which includes drugs from AbbVie (ABBV), Roche (RHHBY), and Bristol Myers Squibb (BMY). The trial, in early-to-mid stages, tests SLS009 alone and in combination. SLS focuses on its Phase 3 Regal trial, nearing final analysis. CEO Angelos Stergiou addressed criticism, emphasizing data over noise. Retail sentiment remains bullish.
How this was made
The 30-second read
Why it matters
The trial update provides a new data point that could influence short‑term price action and investor sentiment.
Market read
Trial update may drive short‑term SLS price movement and signal continued AML combo interest.
What to watch
Potential regulatory hurdles and competition from other CDK9 inhibitors.
Background
Sellas Life Sciences (SLS) is a micro‑cap biotech focused on AML therapies; its stock has surged 558% YTD.
Ticker impact
Updated ClinicalTrials.gov record shows SLS009 trial in AML combined with AbbVie/Roche Venetoclax and BMS Azacitidine, prompting a 2% stock rise.
Potential upside of 5‑10% over the next week if data readout is favorable.
Trial update is a fresh catalyst for a micro‑cap biotech; market reacts quickly to early‑stage data.
Market effects
Highlights continued interest in AML combos with big‑pharma backbones, may spur peer biotech activity.
U.S. biotech sector sees modest lift.
Limited to AML therapeutic space.
Counterpoint
Trial is early‑stage; data may not translate to efficacy, risk of delay or failure.
Key entities
- companySellas Life Sciences
Biotech developing SLS009 for AML.
- companyAbbVie
Provider of Venetoclax (Venclexta).
- companyRoche/Genentech
Co‑developer of Venetoclax.
- companyBristol Myers Squibb
Provider of Azacitidine (Vidaza/Onureg).
